利福布汀与左氧氟沙星联合治疗老年初治涂阳肺结核的疗效

Curative Effect of Rifabutin Combined With Levofloxacin in the Initial Treatment for Elderly Patients with Smear Positive Pulmonary Tuberculosis

目的探讨老年初治涂阳肺结核采用利福布汀和左氧氟沙星联合治疗的临床效果。方法随机选取该院2014年4月—2015年4月间符合标准的初始涂阳肺结核老年患者100例,按照随机数字表法分为治疗组和对照组,每组50例;对照组患者实施利福布汀联合吡嗪酰胺治疗,治疗组患者实施利福布汀联合左氧氟沙星治疗,观察两组患者治疗后的临床效果及不良反应情况。结果两组患者治疗后,病情均有所改善,但治疗组6个月的转阴率86.0%、9个月的转阴率96.0%显著优于对照组的46.0%和72.0%,治疗组的复发率6.0%显著低于对照组的34.0%,治疗组患者的不良反应发生率6.0%显著低于对照组的46.0%,结果具有统计学差异(P<0.05)。结论利福布汀和左氧氟沙星联合治疗老年初治涂阳肺结核,有效的提高了患者的临床转阴率,促进了临床治疗效果,降低了药物的不良反应率,减少了患者的临床痛苦,安全有效,值得临床推广。

Objective To study the clinical effect of Rifabutin combined with Levofloxacin in the initial treatment for elderly patients with smear positive pulmonary tuberculosis. Methods 100 elderly patients with smear positive pulmonary tuberculosis in our hospital from April 2015 to April 2014 who were selected and divided into treatment group and control group according to different therapies, 50 cases each group. The control group adopted Rifabutin combined with Pyrazinamide while treatment group adopted Rifabutin combined with Levofloxacin. The clinical effect and adverse reactions of two groups was observed. Results After treatment, the symptoms of two groups were improved. The rate of turning into smear negative pulmonary tuberculosis of treatment group after 6m and 9m of treatment was 86.0% and 96.0% while the rate of control group was 46.0% and 72.0%. The recurrence rate of treatment group(6.0%) was significantly lower than that of control group(34.0%); the adverse event rate of treatment group(6.0%) was significantly lower than that of control group(46.0%)(P <0.05).Conclusion In the initial treatment for elderly patients with smear positive pulmonary tuberculosis,Rifabutin combined with Levofloxacin can effectively improve the rate of turning into smear negative pulmonary tuberculosis, promote the clinical effect, reduce the adverse event rate and reduce the clinical pains. The safe and efficient method is worthy of clinical promotion.